Overview
The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.
Eligibility
Inclusion Criteria:
- Female, aged 18-75 years;
- Primary breast cancer diagnosed histopathologically;
- Adjuvant chemotherapy regimens include liposomal doxorubicin;
- ECoG PS score: 0-1 points;
- Left ventricular ejection fraction (LVEF) ≥ 55%;
- Estimated survival ≥ 6 months;
- Major organ function is normal, i.e. meets the following criteria:
① And white blood cells ≥ 4.0 × 10 9 / L, neutrophil count (ANC) ≥ 1.5 × 10 9 /L；② Platelets ≥ 100 × 10 9 /L；③ And hemoglobin ≥ 10 g / dl; ④ Serum creatinine ≤ 1.5 × ⑤ the upper limit of normal (ULN) Mmol / L and aspartate transaminase (AST) ≤ 2.5
× ULN；⑥ Alanine transaminase (ALT) ≤ 2.5 × ULN；⑦ Total bilirubin ≤ 1.5 × ULN；⑧ Serum creatinine ≤ 1.5 × ULN；
- Subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up.
Exclusion Criteria:
- Pregnant, lactating patients;
- Breast cancer has been found to have distant metastasis;
- Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders;
- Those with severe infection or active peptic ulcer requiring treatment;
- Allergic to chemotherapy drugs;
- Cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix;
- Severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes;
- Patients who are participating in other clinical trials or within a month.